Gastric & Gastroesophageal Cancer: A Study of FPA144 Combined With Modified FOLFOX6
in Gastric/Gastroesophageal Cancer (FIGHT)
Research Question:
How safe and what is the tolerability of the new investigational compound, called
FPA144, in combination with chemotherapy (a combination of 5-fluorouracil, oxaliplatin,
and leucovorin called mFOLFOX6), for the treatment of gastric and/or gastroesophageal
cancer and other solid tumors?
Basic Study Information
Purpose:
This study consists of 2 phases. The first phase (Phase 1) of the study will be open
to patients who have gastrointestinal cancer and plan to receive a type of chemotherapy
treatment called mFOLFOX6. The second phase (Phase 3) will include patients who have
gastric or gastroesophageal cancer, whose physician plans to administer chemotherapy
(mFOLFOX6) as therapy, and have a tumor that is FGFR2b positive.
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03343301?term=FPA-144&rank=1
Study Reference #: IGIE17107
Lead Researcher (Principal Investigator)
Lead Researcher: Mohamedtaki Tejani, MD
Study Contact Information
Study Coordinator: Chris Le Feber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search